Alan Liddle
Directeur/Membre du Conseil chez HaemaLogiX Pty Ltd.
Profil
Alan Liddle is the founder of Immune System Therapeutics Ltd.
He is currently a Non-Executive Director at HaemaLogiX Pty Ltd.
Mr. Liddle previously worked as a Non-Executive Director at Wallace Absolute Return Ltd.
and Wallace Funds Management Pty Ltd.
He also served as a Non-Executive Director at Minomic International Ltd.
from 2012 to 2018.
Postes actifs de Alan Liddle
| Sociétés | Poste | Début |
|---|---|---|
HaemaLogiX Pty Ltd.
 HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | Directeur/Membre du Conseil | 01/07/2013 |
Anciens postes connus de Alan Liddle
| Sociétés | Poste | Fin |
|---|---|---|
Minomic International Ltd.
 Minomic International Ltd. BiotechnologyHealth Technology Minomic International Ltd. develops diagnostic and imaging products for prostate cancer and diabetes. Its MiCheck test detects a protein that is present on cancer cells by using blood sample. The company was founded in 1974 and is headquartered in Sydney, Australia. | Directeur/Membre du Conseil | 01/06/2018 |
Wallace Funds Management Pty Ltd.
 Wallace Funds Management Pty Ltd. Investment ManagersFinance Wallace Funds Management Pty Ltd. (WFML), incorporated in 2002, is a private company wholly-owned by their founder and staff. WFML is a Sydney-based specialist funds manager.^WFML's major activity is to provide investment manager services to Wallace Absolute Return Ltd. (WAB), an ASX-listed absolute return hedge fund initially listed in 2003.^The firm also provides investment management services on private mandates as well as risk management services to other clients. | Directeur/Membre du Conseil | 25/03/2009 |
Immune System Therapeutics Ltd.
 Immune System Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Immune System Therapeutics Ltd. engages in the development and commercialization of monoclonal antibodies to treat human blood cancers. The company was founded by Alan Liddle and Rosanne Dunn and is headquartered in Ultimo, Australia. | Fondateur | - |
Wallace Absolute Return Ltd.
 Wallace Absolute Return Ltd. Investment Trusts/Mutual FundsMiscellaneous Wallace Absolute Return Ltd. is engaged in investment funds and investment trust. It invests in quoted and unquoted company's that combines the income yield and capital growth. Wallace Absolute Return is headquartered in Sydney, Australia. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Wallace Absolute Return Ltd.
Wallace Absolute Return Ltd. Investment Trusts/Mutual FundsMiscellaneous Wallace Absolute Return Ltd. is engaged in investment funds and investment trust. It invests in quoted and unquoted company's that combines the income yield and capital growth. Wallace Absolute Return is headquartered in Sydney, Australia. | Miscellaneous |
Wallace Funds Management Pty Ltd.
Wallace Funds Management Pty Ltd. Investment ManagersFinance Wallace Funds Management Pty Ltd. (WFML), incorporated in 2002, is a private company wholly-owned by their founder and staff. WFML is a Sydney-based specialist funds manager.^WFML's major activity is to provide investment manager services to Wallace Absolute Return Ltd. (WAB), an ASX-listed absolute return hedge fund initially listed in 2003.^The firm also provides investment management services on private mandates as well as risk management services to other clients. | Finance |
Minomic International Ltd.
Minomic International Ltd. BiotechnologyHealth Technology Minomic International Ltd. develops diagnostic and imaging products for prostate cancer and diabetes. Its MiCheck test detects a protein that is present on cancer cells by using blood sample. The company was founded in 1974 and is headquartered in Sydney, Australia. | Health Technology |
Immune System Therapeutics Ltd.
Immune System Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Immune System Therapeutics Ltd. engages in the development and commercialization of monoclonal antibodies to treat human blood cancers. The company was founded by Alan Liddle and Rosanne Dunn and is headquartered in Ultimo, Australia. | Health Technology |
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | Health Technology |